Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

It is now well documented that changes in gut microbiota composition accompany obesity and type 2 diabetes (T2D) and contribute to low-grade inflammation, insulin resistance,and glucose intolerance. It is not yet clear if T2D predisposes the intestine to allow more microbial products or possibly live bacteria to subvert the gut mucosal barrier. However, it is known that hyperglycemia during T2D induces a more permissive gut barrier allowing increased penetration of microbes and their products into the blood. An important next step is to determine which strains of bacteria promote dysbiosis, allowing bacteria or bacterial components to subvert the gut barrier and alter glucose control. It is hypothesized that gut microbes in the colon and other lower gut segments are key modulators of energy balance, glucose homeostasis and insulin sensitivity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:

• T2DB de novo or non T2DB patients

Locations
Other Locations
Canada
INAF, Université Laval
RECRUITING
Québec
Contact Information
Primary
Geneviève Pilon, PhD
Genevieve.Pilon@criucpq.ulaval.ca
418-656-8711
Time Frame
Start Date: 2021-02-01
Estimated Completion Date: 2025-12-01
Participants
Target number of participants: 40
Treatments
Experimental: Type 2 Diabetes patients
Upper gut biopsies and lower gut samples
Active_comparator: Non Type 2 Diabetes patients
Upper gut biopsies and lower gut samples
Related Therapeutic Areas
Sponsors
Leads: Laval University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials